DexCom (NASDAQ:DXCM) Upgraded to Buy by StockNews.com

DexCom (NASDAQ:DXCM - Get Free Report) was upgraded by investment analysts at StockNews.com from a "hold" rating to a "buy" rating in a report issued on Wednesday.

DXCM has been the topic of a number of other reports. Canaccord Genuity Group increased their price objective on DexCom from $144.00 to $145.00 and gave the company a "buy" rating in a research report on Friday, April 26th. Raymond James increased their price objective on DexCom from $151.00 to $160.00 and gave the company a "strong-buy" rating in a research report on Friday, April 26th. UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the company a "buy" rating in a research report on Wednesday, April 10th. Royal Bank of Canada started coverage on DexCom in a research note on Tuesday, March 12th. They issued an "outperform" rating and a $165.00 price target on the stock. Finally, Citigroup increased their price target on DexCom from $148.00 to $161.00 and gave the company a "buy" rating in a research note on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $141.67.

DexCom Price Performance

NASDAQ DXCM traded down $1.51 during trading hours on Wednesday, reaching $125.88. 2,916,340 shares of the company's stock were exchanged, compared to its average volume of 3,055,031. The stock has a market cap of $50.06 billion, a PE ratio of 82.19, a price-to-earnings-growth ratio of 2.14 and a beta of 1.20. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. The firm has a fifty day moving average of $131.49 and a 200-day moving average of $119.53. DexCom has a one year low of $74.75 and a one year high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. On average, equities research analysts predict that DexCom will post 1.77 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Kevin R. Sayer sold 81,007 shares of the firm's stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the transaction, the chief executive officer now owns 333,526 shares in the company, valued at approximately $44,479,027.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the transaction, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now owns 42,377 shares of the company's stock, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. Insiders sold 189,375 shares of company stock worth $25,530,859 in the last quarter. Corporate insiders own 0.41% of the company's stock.

Hedge Funds Weigh In On DexCom

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cary Street Partners Investment Advisory LLC lifted its position in DexCom by 11.1% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company's stock worth $108,000 after acquiring an additional 115 shares during the last quarter. CX Institutional acquired a new stake in DexCom during the fourth quarter worth approximately $286,000. abrdn plc lifted its position in DexCom by 21.1% during the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company's stock worth $47,221,000 after acquiring an additional 66,348 shares during the last quarter. Cerity Partners LLC lifted its position in DexCom by 5,791.0% during the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company's stock worth $57,574,000 after acquiring an additional 456,097 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in DexCom during the fourth quarter worth approximately $57,000. Institutional investors own 97.75% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.